{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:32:47Z","timestamp":1784064767976,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sichuan provincial health department","award":["140078"],"award-info":[{"award-number":["140078"]}]},{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2018LY05"],"award-info":[{"award-number":["2018LY05"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Idiopathic membranous nephropathy (IMN) remains the leading cause of adult nephrotic syndrome. Immunosuppressive therapy with cyclophosphamide (CTX) is often successful in reducing proteinuria, but its use is associated with severe side effects. Tacrolimus (TAC) is effective in achieving complete remission (CR) in patients with IMN. However, whether it is as effective as CTX in inducing and maintaining complete or partial remission in these patients is unknown. This trial aims to test TAC monotherapy for its non-inferiority to CTX in inducing long-term remission of proteinuria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with biopsy-proven IMN with nephrotic syndrome will be randomized into a 12-month treatment period with oral TAC of 0.05\u20130.1\u2009mg\/kg\/day for 6\u2009months or with CTX\u2009+\u2009glucocorticoid. The efficacy of the treatment will be assessed by the remission status (based on changes in proteinuria) and relapse rate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study will test whether treatment with TAC monotherapy is superior to CTX with glucocorticoid in inducing long-term remission of proteinuria in patients with adult IMN. The role of serum anti-PLA2R antibodies in the early assessment of the response to therapy using different therapeutic regimens will also be clarified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinicalTrials.gov ChiCTR1800016140. Registered 12 June 2017.<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\">http:\/\/www.chictr.org.cn<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13063-020-4144-3","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T16:09:09Z","timestamp":1582560549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study"],"prefix":"10.1186","volume":"21","author":[{"given":"Shasha","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hieu","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqing","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"4144_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0272-6386(97)90485-6","volume":"30","author":"M Haas","year":"1997","unstructured":"Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997;30:621\u201331.","journal-title":"Am J Kidney Dis."},{"key":"4144_CR2","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/ndt\/gfn554","volume":"24","author":"FD Zhou","year":"2009","unstructured":"Zhou FD, Zhao MH, Zou WZ, Liu G, Wang HJNDT. The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant. 2009;24:870\u20136.","journal-title":"Nephrol Dial Transplant."},{"key":"4144_CR3","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1093\/ndt\/gfr398","volume":"26","author":"M Mubarak","year":"2011","unstructured":"Mubarak M. The renal histopathological spectrum of patients with nephrotic syndrome: an analysis of 1523 patients in a single Chinese centre. Nephrol Dial Transplant. 2011;26:3419 author reply 19-20.","journal-title":"Nephrol Dial Transplant."},{"key":"4144_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.2215\/CJN.01330209","volume":"4","author":"MA Hladunewich","year":"2009","unstructured":"Hladunewich MA, Troyanov S, Calafati J, Cattran DC. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol. 2009;4:1417\u201322.","journal-title":"Clin J Am Soc Nephrol."},{"key":"4144_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/ki.1988.56","volume":"33","author":"DJ Jr","year":"1988","unstructured":"Jr DJ, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, et al. Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int. 1988;33:708\u201315.","journal-title":"Kidney Int."},{"key":"4144_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","volume":"23","author":"RJ Glassock","year":"2003","unstructured":"Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003;23:324\u201332.","journal-title":"Semin Nephrol."},{"key":"4144_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/kisup.2012.20","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. Chapter 7: Idiopathic membranous nephropathy. Kidney Int Suppl. 2012;2:186\u201397.","journal-title":"Kidney Int Suppl"},{"key":"4144_CR8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","volume":"9","author":"C Ponticelli","year":"1998","unstructured":"Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol. 1998;9:444\u201350.","journal-title":"J Am Soc Nephrol."},{"key":"4144_CR9","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/ki.1995.453","volume":"48","author":"CJKI Pozzi","year":"1995","unstructured":"Pozzi CJKI. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995;48:1600.","journal-title":"Kidney Int."},{"key":"4144_CR10","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1681\/ASN.2007020166","volume":"18","author":"V Jha","year":"2007","unstructured":"Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18:1899\u2013904.","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"4144_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jfma.2015.07.021","volume":"115","author":"P Lei","year":"2016","unstructured":"Lei P, Shi-Yao W, Lei-Ting L, et al. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy. J Formos Med Assoc. 2016;115(1):11\u20138.","journal-title":"J Formos Med Assoc"},{"key":"4144_CR12","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","volume":"339","author":"M Chen","year":"2010","unstructured":"Chen M, Wang HY, Li H, Li XW, Li XY, Chen JH, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010;339:233.","journal-title":"Am J Med Sci"},{"key":"4144_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/qjmed\/91.5.359","volume":"91","author":"AJ Branten","year":"1998","unstructured":"Branten AJ, Reichert LJ, Koene RA, Wetzels JF. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM. 1998;91:359.","journal-title":"QJM"},{"key":"4144_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","volume":"339","author":"M Chen","year":"2010","unstructured":"Chen M, Li H, Li XY, Lu FM, Ni ZH, Xu FF, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy:a multicenter randomized controlled trial. Am J Med Sci. 2010;339:233\u20138.","journal-title":"Am J Med Sci."},{"key":"4144_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"M Praga","year":"2007","unstructured":"Praga M, Barrio V, Juarez GF, Luno J, Grupo Espanol de Estudio de la Nefropatia Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71:924\u201330.","journal-title":"Kidney Int"},{"key":"4144_CR16","first-page":"584","volume":"21","author":"X Li","year":"2008","unstructured":"Li X, Lv R, He Q, Li H, Du X, Lin W, et al. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria. J Nephrol. 2008;21:584\u201391.","journal-title":"J Nephrol."},{"key":"4144_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184398","volume":"12","author":"S Ren","year":"2017","unstructured":"Ren S, Wang Y, Xian L, Toyama T, Jardine M, Li G, et al. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: a network meta-analysis. PLoS One. 2017;12:e0184398.","journal-title":"PLoS One."},{"key":"4144_CR18","doi-asserted-by":"crossref","unstructured":"van den Brand JAJG, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, Wetzels JFM, Remuzzi G. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J Am Soc Nephrol. 2017;28:2729\u201337.","DOI":"10.1681\/ASN.2016091022"},{"key":"4144_CR19","doi-asserted-by":"crossref","unstructured":"van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol. 2014; 25:150-158.","DOI":"10.1681\/ASN.2013020185"},{"issue":"6","key":"4144_CR20","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.2215\/CJN.08880813","volume":"9","author":"JA van den Brand","year":"2014","unstructured":"van den Brand JA, van Dijk PR, Hofstra JM, Wetzels JF. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(6):1066\u201373.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4144_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1080\/0886022X.2017.1325371","volume":"39","author":"Q Liang","year":"2017","unstructured":"Liang Q, Li H, Xie X, Qu F, Li X, Chen J. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Ren Fail. 2017;39:512\u20138.","journal-title":"Ren Fail."},{"key":"4144_CR22","unstructured":"Levin A, Stevens PE, Bilous RW, Coresh J, Winearls CG. Kidney disease: improving global outcomes (kdigo) ckd work group. kdigo 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1\u2013150."},{"key":"4144_CR23","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1136\/ard.2003.019125","volume":"63","author":"A Knight","year":"2004","unstructured":"Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis. 2004;63:1307\u201311.","journal-title":"Ann Rheum Dis."},{"key":"4144_CR24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.V95842","volume":"9","author":"KW Westman","year":"1998","unstructured":"Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9:842\u201352.","journal-title":"J Am Soc Nephrol."},{"key":"4144_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/nep.12569","volume":"21","author":"R Ramachandran","year":"2016","unstructured":"Ramachandran R, Hn HK, Kumar V, Nada R, Yadav AK, Goyal A, et al. Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial. Nephrology (Carlton). 2016;21:139\u201346.","journal-title":"Nephrology (Carlton)"},{"key":"4144_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000348475","volume":"181","author":"J Xu","year":"2013","unstructured":"Xu J, Zhang W, Xu Y, Shen P, Ren H, Wang W, et al. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial. Contrib Nephrol. 2013;181:152\u201362.","journal-title":"Contrib Nephrol."},{"issue":"4","key":"4144_CR27","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/ndt\/14.4.1036","volume":"14","author":"L Fritsche","year":"1999","unstructured":"Fritsche L, Budde K, F\u00e4rber L, Chariss\u00e9 G, Kunz R, Gaedeke J, et al. Treatment of membranous glomerulopathy with cyclosporin A: How much patience is required? Nephrol Dial Transplant. 1999;14(4):1036\u20138.","journal-title":"Nephrol Dial Transplant"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4144-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-020-4144-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-4144-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T11:04:07Z","timestamp":1665918247000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-4144-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4144"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-4144-3","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"10 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Central ethical approval has been confirmed from the medical ethics committee of the Sichuan Academy of Medical Sciences and Sichuan Provincial People\u2019s Hospital, and we will not begin recruiting at the other centers in the trial until local ethical approval has been obtained, and informed written consent will be obtained from all of the identified patients for the treatment they receive.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}